Education
About Us
Working with TipRanks
Follow Us
Shanghai Henlius Biotech, Inc. Class H (HK:2696)
:2696
2696 Stock Chart & Stats
HK$69.85
HK$0.05(0.21%)
At close: 4:00 PM EST
HK$69.85
HK$0.05(0.21%)
Day’s Range― - ―
52-Week RangeHK$15.20 - HK$92.00
Previous CloseN/A
Volume849.10K
Average Volume (3M)1.53M
Market Cap
HK$38.94B
Enterprise ValueHK$31.74B
Total Cash (Recent Filing)HK$972.50M
Total Debt (Recent Filing)HK$3.67B
Price to Earnings (P/E)43.8
Beta0.54
Next Earnings
Aug 25, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding163,428,540
10 Day Avg. Volume1,665,497
30 Day Avg. Volume1,532,406
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)4.01
Price to Sales (P/S)2.11
P/FCF Ratio29.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$107.87Price Target Upside54.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Financial PerformanceA global biosimilar franchise is expected to provide meaningful cash flow to drive R&D.
Pipeline ExpansionThe transition is well supported by an expanding pipeline led by key assets HLX43, which emerges as a potential best-in-class pan-tumor PD-L1 ADC poised for global pivotal studies.
Strategic EvolutionHenlius Biotech is strategically evolving from an early mover in biosimilar to a global innovative biopharma.
Bears Say
Shanghai Henlius Biotech, Inc. Class H News
2696 FAQ
What was Shanghai Henlius Biotech, Inc. Class H’s price range in the past 12 months?
Shanghai Henlius Biotech, Inc. Class H lowest stock price was HK$15.20 and its highest was HK$92.00 in the past 12 months.
What is Shanghai Henlius Biotech, Inc. Class H’s market cap?
Shanghai Henlius Biotech, Inc. Class H’s market cap is HK$38.94B.
When is Shanghai Henlius Biotech, Inc. Class H’s upcoming earnings report date?
Shanghai Henlius Biotech, Inc. Class H’s upcoming earnings report date is Aug 25, 2025 which is 70 days ago.
How were Shanghai Henlius Biotech, Inc. Class H’s earnings last quarter?
Shanghai Henlius Biotech, Inc. Class H released its earnings results on Mar 24, 2025. The company reported HK$0.867 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.867.
Is Shanghai Henlius Biotech, Inc. Class H overvalued?
According to Wall Street analysts Shanghai Henlius Biotech, Inc. Class H’s price is currently Undervalued.
Does Shanghai Henlius Biotech, Inc. Class H pay dividends?
Shanghai Henlius Biotech, Inc. Class H does not currently pay dividends.
What is Shanghai Henlius Biotech, Inc. Class H’s EPS estimate?
Shanghai Henlius Biotech, Inc. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shanghai Henlius Biotech, Inc. Class H have?
Shanghai Henlius Biotech, Inc. Class H has 163,428,540 shares outstanding.
What happened to Shanghai Henlius Biotech, Inc. Class H’s price movement after its last earnings report?
Shanghai Henlius Biotech, Inc. Class H reported an EPS of HK$0.867 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -4.132%.
Which hedge fund is a major shareholder of Shanghai Henlius Biotech, Inc. Class H?
Currently, no hedge funds are holding shares in HK:2696
Shanghai Henlius Biotech, Inc. Class H Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
217.03%
12-Months-Change
Fundamentals
Return on Equity
27.37%
Trailing 12-Months
Asset Growth
18.00%
Trailing 12-Months
Company Description
Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. Class H (2696) is a leading biopharmaceutical company based in China, specializing in the research, development, manufacturing, and commercialization of monoclonal antibody (mAb) biosimilars and innovative biologics. The company operates in the biotechnology and pharmaceutical sectors, focusing on providing affordable and high-quality biologic drugs to treat cancer, autoimmune diseases, and other serious conditions. Henlius is committed to enhancing global healthcare access through its robust pipeline of biosimilar and novel therapeutic products.
2696 Stock 12 Month Forecast
Average Price Target
HK$107.87
▲(54.43% Upside)
Technical Analysis
Zai Lab Ltd
―
InnoCare Pharma Ltd.
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Simcere Pharmaceutical Group Limited
―
Ascentage Pharma Group International
―
Options Prices
Currently, No data available
---